No decrease in CD4/CD8 ratio after 36 months therapy in patients switched to dual regimens containing rilpivirine

Enferm Infecc Microbiol Clin (Engl Ed). 2021 Feb;39(2):106-107. doi: 10.1016/j.eimc.2020.04.004. Epub 2020 May 31.

[Article in English, Spanish]

Authors

Cecilia Tortajada¹, Lidia Castellano², Amando Mengual³, Juan Flores²

Affiliations

¹ Infectious Disease Unit, Internal Medicine Department, Hospital Arnau de Vilanova, Valencia, Spain. Electronic address: ctortaja@gmail.com.
² Infectious Disease Unit, Internal Medicine Department, Hospital Arnau de Vilanova, Valencia, Spain.
³ Department of Pharmacy, Hospital Arnau de Vilanova, Valencia, Spain.

PMID: 32493571
DOI: 10.1016/j.eimc.2020.04.004

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Anti-HIV Agents* / therapeutic use
CD4-CD8 Ratio
CD8-Positive T-Lymphocytes
HIV Infections* / drug therapy
Humans
Rilpivirine / therapeutic use

Substances

Anti-HIV Agents
Rilpivirine